Capitolis Liquid Global Markets’s Vertex Pharmaceuticals VRTX Stock Holding History

Capitolis Liquid Global Markets’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.5M	Buy	16,806 +3,991	+31%	+$1.86M	0.05%	213
2025 Q4	$5.81M	Buy	+12,815	New	+$5.52M	0.03%	200
2025 Q3	–	Sell	-71,000	Closed	-$31.6M	–	321
2025 Q2	$31.6M	Buy	+71,000	New	+$32.7M	0.23%	75
2025 Q1	–	Sell	-25,000	Closed	-$10.1M	–	222
2024 Q4	$10.1M	Hold	25,000	–	–	0.1%	87
2024 Q3	$11.6M	Sell	25,000 -10,000	-29%	-$4.8M	0.12%	71
2024 Q2	$16.4M	Sell	35,000 -15,000	-30%	-$6.51M	0.2%	64
2024 Q1	$20.9M	Sell	50,000 -60,000	-55%	-$25.4M	0.34%	55
2023 Q4	$44.8M	Buy	+110,000	New	+$40.6M	1.84%	17

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capitolis Liquid Global Markets's VRTX Position: Q1 2026 in Review

Capitolis Liquid Global Markets increased its Vertex Pharmaceuticals (VRTX) stake by 31% in Q1 2026, buying an estimated $1.86M and bringing the position to 16,806 shares worth $7.5M. The position accounts for 0.05% of the portfolio, ranked #213.

Capitolis Liquid Global Markets first reported a position in VRTX in Q4 2023 and has held it in 8 quarters since. The position peaked at $44.8M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Capitolis Liquid Global Markets held 16,806 shares of Vertex Pharmaceuticals worth $7.5M as of Q1 2026.
Capitolis Liquid Global Markets bought 3,991 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.86M.
Vertex Pharmaceuticals made up 0.05% of Capitolis Liquid Global Markets's portfolio in Q1 2026, its #213 holding.
Capitolis Liquid Global Markets first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Capitolis Liquid Global Markets's Vertex Pharmaceuticals position peaked at $44.8M in Q4 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Capitolis Liquid Global Markets's 13F filing for Q1 2026, filed 15 May 2026.